MMSI Quote, Financials, Valuation and Earnings

Integra LifeSciences Holdings Corp. has a net margin of 7.22% compared to Merit Medical Systems, Inc.'s net margin of -1.34%. Merit Medical Systems, Inc.'s return on equity of 8.28% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Merit Medical Systems, Inc. has a consensus price target of $103.60, signalling upside risk potential of 17.83%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 23.31%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Merit Medical Systems, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Merit Medical Systems, Inc..

Merit Medical Systems, Inc. has a beta of 0.615, which suggesting that the stock is 38.504% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.

Merit Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merit Medical Systems, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Merit Medical Systems, Inc. quarterly revenues are $384.3M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Merit Medical Systems, Inc.'s net income of $27.8M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Merit Medical Systems, Inc.'s price-to-earnings ratio is 45.00x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems, Inc. is 3.61x versus 0.59x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 7.22% compared to Merit Medical Systems, Inc.'s net margin of 14.46%. Merit Medical Systems, Inc.'s return on equity of 8.28% beat Masimo Corp.'s return on equity of -19.18%.

Merit Medical Systems, Inc. has a consensus price target of $103.60, signalling upside risk potential of 17.83%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 34.12%. Given that Masimo Corp. has higher upside potential than Merit Medical Systems, Inc., analysts believe Masimo Corp. is more attractive than Merit Medical Systems, Inc..

Merit Medical Systems, Inc. has a beta of 0.615, which suggesting that the stock is 38.504% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Merit Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merit Medical Systems, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Merit Medical Systems, Inc. quarterly revenues are $384.3M, which are larger than Masimo Corp. quarterly revenues of $371.5M. Merit Medical Systems, Inc.'s net income of $27.8M is lower than Masimo Corp.'s net income of $53.7M. Notably, Merit Medical Systems, Inc.'s price-to-earnings ratio is 45.00x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems, Inc. is 3.61x versus 4.33x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 7.22% compared to Merit Medical Systems, Inc.'s net margin of 12.4%. Merit Medical Systems, Inc.'s return on equity of 8.28% beat Insulet Corp.'s return on equity of 18.92%.

Merit Medical Systems, Inc. has a consensus price target of $103.60, signalling upside risk potential of 17.83%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 29.55%. Given that Insulet Corp. has higher upside potential than Merit Medical Systems, Inc., analysts believe Insulet Corp. is more attractive than Merit Medical Systems, Inc..

Merit Medical Systems, Inc. has a beta of 0.615, which suggesting that the stock is 38.504% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Merit Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merit Medical Systems, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Merit Medical Systems, Inc. quarterly revenues are $384.3M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Merit Medical Systems, Inc.'s net income of $27.8M is lower than Insulet Corp.'s net income of $87.6M. Notably, Merit Medical Systems, Inc.'s price-to-earnings ratio is 45.00x while Insulet Corp.'s PE ratio is 84.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems, Inc. is 3.61x versus 8.37x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of 7.22% compared to Merit Medical Systems, Inc.'s net margin of -8.49%. Merit Medical Systems, Inc.'s return on equity of 8.28% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Merit Medical Systems, Inc. has a consensus price target of $103.60, signalling upside risk potential of 17.83%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 6.66%. Given that Merit Medical Systems, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Merit Medical Systems, Inc. is more attractive than Tandem Diabetes Care, Inc..

Merit Medical Systems, Inc. has a beta of 0.615, which suggesting that the stock is 38.504% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.

Merit Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merit Medical Systems, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Merit Medical Systems, Inc. quarterly revenues are $384.3M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Merit Medical Systems, Inc.'s net income of $27.8M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Merit Medical Systems, Inc.'s price-to-earnings ratio is 45.00x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems, Inc. is 3.61x versus 1.54x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.